BD-PT0929

CIITA Rabbit Polyclonal Antibody

CIITA; MHC2TA; MHC class II transactivator; CIITA

常规抗体

CIITA

MHC class II transactivator

WB

Human,Mouse,Rat

1 mg/ml

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N.

4261

http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&term=4261

P33076

http://www.uniprot.org/uniprotkb/P33076/entry

12265

http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&term=12265

P79621

http://www.uniprot.org/uniprot/P79621

The antiserum was produced against synthesized peptide derived from human CIITA. AA range:706-755

CIITA Polyclonal Antibody detects endogenous levels of CIITA protein.

WB 1:500 - 1:2000. ELISA: 1:10000. Not yet tested in other applications.

123kD

-20°C/1 year

Polyclonal, Rabbit,IgG

class II major histocompatibility complex transactivator(CIITA) Homo sapiens This gene encodes a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the "master control factor" for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardi

Nucleus . Nucleus, PML body . Recruited to PML body by PML.

Antigen processing and presentation;Primary immunodeficiency;

disease:Defects in CIITA are a cause of bare lymphocyte syndrome type 2 (BLS2) [MIM:209920]; also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency. BLS2 is a severe combined immunodeficiency disease with early onset. It is characterized by a profound defect in constitutive and interferon-gamma induced MHC II expression, absence of cellular and humoral T-cell response to antigen challenge, hypogammaglobulinemia and impaired antibody production. The consequence include extreme susceptibility to viral, bacterial and fungal infections.,function:Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter. No DNA binding of in vitro translated CIITA was detected. May act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II promoter, to elements of the transcription machinery, or both. Alternatively it may activate HLA class II transcription by modifying proteins that bind to the MHC class II promoter.,online information:CIITA mutation db,similarity:Contains 1 NACHT domain.,similarity:Contains 4 LRR (leucine-rich) repeats.,subunit:Interacts with ZXDA and ZXDC.,

现货

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.